Hemostasis Today

April, 2026
April 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
27282930  
Mohammed M. Aboudeif: The Decision-Making Process for Anticoagulation in Stroke
Apr 18, 2026, 13:16

Mohammed M. Aboudeif: The Decision-Making Process for Anticoagulation in Stroke

Mohammed M. Aboudeif, Critical Care Registrar at King AbdulAziz University, shared on LinkedIn:

”Timing is often the most critical factor in neurocritical care, especially when balancing the risk of recurrent ischemia against the threat of hemorrhagic transformation.

​Standardizing the transition from acute management to long-term prevention is essential for patient safety and clinical excellence.

This visual guide breaks down the decision-making process for Anticoagulation in Stroke, specifically focusing on the initiation of DOACs in patients with Atrial Fibrillation (AF).

​Key Takeaways for the Clinical Team:

  • ​The Acute Phase (0-48h): A universal ‘No’ for anticoagulation.
  • The focus remains on stabilization, hydration, and DVT prophylaxis (IPC preferred).

​Ischemic Stroke and AF

The 1-3-6-12 Rule remains a vital framework for starting DOACs based on stroke severity:

  • ​Day 1: TIA
  • ​Day 3: Mild (NIHSS <8)
  • ​Day 6: Moderate (NIHSS 8-15)
  • ​Day 12: Severe (NIHSS >15)

​Hemorrhagic Stroke: A much more conservative approach.

Restarting anticoagulation is generally deferred for 2–4 weeks and reserved for those with high embolic risk (e.g., mechanical valves), requiring careful reassessment of re-bleeding risk.

​Standardized protocols like these reduce clinical variability and improve outcomes in the ICU and beyond.”

Mohammed M. Aboudeif: The Decision-Making Process for Anticoagulation in Stroke

Stay updated with Hemostasis Today.